Article thumbnail

Suitable carriers for encapsulation and distribution of endostar: comparison of endostar-loaded particulate carriers

By Weijie Chen and Sanyuan Hu
Topics: Original Research
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:3152471
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. A multicenter, randomized, doubleblind, placebo-controlled study to evaluate the efficacy of paclitaxelcarboplatin alone or with endostar for advanced non-small cell lung cancer.
  2. All-trans-retinoic acid release from core-shell type nanoparticles of poly(epsilon- caprolactone)/poly(ethylene glycol) diblock copolymer.
  3. characterization and in-vitro evaluation of sustained release protein-loaded nanoparticles based on biodegradable polymers.
  4. Characterization of a monoPEG20000-Endostar.
  5. Clinical pharmacology of methadone in dogs. Vet Anaesth Analg.
  6. (2010). Combined chemoimmunotherapy as a prospective strategy to combat cancer: a nanoparticle based approach. Mol Pharm.
  7. (2001). Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res.
  8. (2003). Continuous versus intermittent administration of human endostatin in xenografted human neuroblastoma. J Pediatr Surg.
  9. (1991). Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm Res.
  10. Development and characterization of CyA-loaded poly(lactic acid)-poly(ethylene glycol)PEG micro- and nanoparticles. Comparison with conventional PLA particulate carriers.
  11. Effect of medium-chain triglycerides on the release behavior of Endostar encapsulated PLGA microspheres.
  12. Effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide.
  13. Endostar-loaded PEG-PLGA nanoparticles: in vitro and in vivo evaluation.
  14. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells.
  15. Endostatin inhibits tumour lymphangiogenesis and lymphatic metastasis via cell surface nucleolin on lymphangiogenic endothelial cells.
  16. (1999). Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro.
  17. Microspheres made by w/o/o emulsion method with reduced initial burst for long-term delivery of endostar, a novel recombinant human endostatin.
  18. (2007). Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol.
  19. Nanoparticles based on PLGA and its co-polymer: an overview.
  20. (2009). Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim Biophys Acta.
  21. (2007). Nanotechnology for targeted cancer therapy. Expert Rev Anticancer Ther.
  22. (2007). Optimizing drug delivery for enhancing therapeutic efficacy of recombinant human endostatin in cancer treatment. Crit Rev Ther Drug Carrier Syst.
  23. (2005). Pharmacokinetics of His-tag recombinant human endostatin in Rhesus monkeys. Acta Pharmacol Sin.
  24. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors.
  25. (2011). Phase II study of cisplatin/ etoposide and endostar for extensive-stage small-cell lung cancer. Cancer Chemother Pharmacol.
  26. Poly(ethylene glycol)- blockpolyethylenimine copolymers as carriers for gene delivery: effects of PEG molecular weight and PEGylation degree.
  27. Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles.
  28. Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery.
  29. (1998). Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment.
  30. (2003). Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res.
  31. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov.
  32. Sustained delivery of endostatin improves the efficacy of therapy in Lewis lung cancer model.
  33. Targeting nanoparticles to cancer. Pharmacol Res.
  34. The blue complexes of iodine with poly(vinyl alcohol) and amylose.
  35. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices.